global provider of customized laboratory and research services


KRAS Mutation Detection Assays

We provide KRAS mutation detection assay on paraffin block tissue samples (standard material used in the post-operative analysis of tumour samples).

The protein product of the normal KRAS gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers.


If the candidate meets the following criteria, KRAS Mutation Detection test could be available:

  • Patient has been diagnosed with metastatic colorectal cancer.
  • Patient has failed on fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
  • Patient will be prescribed Vectibix™ or Erbitux® if the results of the KRAS test indicate the tumor is non-mutated (wild-type) KRAS.

Other Indications

Other indications when KRAS Mutation Detection would be helpful include:

  • Patients currently treated with Vectibix™ (panitumumab) or Erbitux® (cetuximab) for colorectal cancer (or prior to commencing treatment).
  • Patients with lung cancer under treatment with tyrosine kinase inhibitors such as Iressa™ (AstraZeneca) or Tarceva™ (Roche/OSI Pharmaceuticals).

More Information

For Health Care Practitioners who require more information on Vectibix®, please visit Amgen Canada’s website.

General information for patients about KRAS testing is available through Colorectal Cancer Coalition website .

Colon Cancer

KRAS Mutation Detection in Treatment of Colorectal Cancer

KRAS Mutation Detection Assay




KRAS Requisition Forms

These requisition forms are fillable PDFs. You can complete the forms by typing your information in the provided fields, then print a hard copy for faxing. You will not be submitting your information online.